leisure time -WSS

leisure time

author：focus 2025-10-01 21:36:19 - browse：4

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Oak trusses raised to roof of fire

WSS

Cell therapy fails to slow type 1 diabetes, but safety is established

FTC falls short on scrutinizing hospital mergers, study says

Why rehabilitation engineers need to center patients in their research

N.Y. state detects polio case, first in the U.S. since 2013

Cue Health's Covid

More tobacco lobbyists active in statehouses

hotspot

leisure time

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Leqembi, other new Alzheimer’s drugs require better biomarkers

Jerome Adams on the need for new antivirals for Covid

FTC falls short on scrutinizing hospital mergers, study says

Cancer drug shortages should be causing more outrage

Why 40% Americans with Parkinson’s don’t see a neurologist

Walensky prepares to leave CDC — and Congress — behind

N.Y. state detects polio case, first in the U.S. since 2013

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Element Biosciences CEO lays out genome sequencing strategy

knowledge

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Diversity in clinical trials starts with building trust, experts say

Melinda French Gates resigns from Gates Foundation

UnitedHealth financials solid despite Change Healthcare cyberattack

Key Senate committee drafts bipartisan bill to stem drug shortages

hotspot

knowledge

Wikipedia

hotspot